Literature DB >> 27480779

Events of Molecular Changes in Epithelial-Mesenchymal Transition.

Srishti Kotiyal1, Susinjan Bhattacharya1.   

Abstract

EMT is the process by which epithelial cells, characterized by well-developed intercellular contacts, transdifferentiate into motile and invasive mesenchymal cells. This process is associated with the loss of transmembrane intercellular adhesion molecule E-cadherin and disruption of cell-cell junctions along with acquisition of migratory properties. EMT is integral in embryonic development, wound healing, and stem cell behavior; however, its aberrant activation by micro-environmental alterations and abnormal stimuli can lead to cancer progression. Here, we review the different molecular changes associated with EMT that are responsible for downregulation of epithelial genes. Increased knowledge of the EMT process is essential for therapeutic targeting of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27480779     DOI: 10.1615/CritRevEukaryotGeneExpr.2016016307

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  9 in total

1.  ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.

Authors:  Tiansuo Zhao; Wenna Jiang; Xiuchao Wang; Hongwei Wang; Chen Zheng; Yang Li; Yan Sun; Chongbiao Huang; Zhi-Bo Han; Shengyu Yang; Zhiliang Jia; Keping Xie; He Ren; Jihui Hao
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

2.  Overexpression Pattern of miR-301b in Osteosarcoma and Its Relevance with Osteosarcoma Cellular Behaviors via Modulating SNX10.

Authors:  Yaozong Wang; Naikun Sun; Zheyi Zhang; Yuanyuan Zhou; Hongyi Liu; Xu Zhou; Ying Zhang; Yilin Zhao
Journal:  Biochem Genet       Date:  2022-06-22       Impact factor: 1.890

Review 3.  Does CCL19 act as a double-edged sword in cancer development?

Authors:  Arezoo Gowhari Shabgah; Zaid Mahdi Jaber Al-Obaidi; Heshu Sulaiman Rahman; Walid Kamal Abdelbasset; Wanich Suksatan; Dmitry O Bokov; Lakshmi Thangavelu; Abduladheem Turki Jalil; Farhad Jadidi-Niaragh; Hamed Mohammadi; Kazem Mashayekhi; Jamshid Gholizadeh Navashenaq
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

4.  CCR7 mediates human breast cancer cell invasion, migration by inducing epithelial-mesenchymal transition and suppressing apoptosis through AKT pathway.

Authors:  Bing Xu; Minjie Zhou; Wencai Qiu; Jueming Ye; Qiming Feng
Journal:  Cancer Med       Date:  2017-04-04       Impact factor: 4.452

5.  Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.

Authors:  Zhigang Yi; Yanchuan Pu; Ruoyan Gou; Yonggang Chen; Xiaojun Ren; Wenzhong Liu; Ping Dong
Journal:  Mol Med Rep       Date:  2020-01-14       Impact factor: 2.952

6.  DCBLD2 Affects the Development of Colorectal Cancer via EMT and Angiogenesis and Modulates 5-FU Drug Resistance.

Authors:  Pan Xie; Fu-Qiang Yuan; Ma-Sha Huang; Wei Zhang; Hong-Hao Zhou; Xi Li; Zhao-Qian Liu
Journal:  Front Cell Dev Biol       Date:  2021-05-19

7.  FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.

Authors:  Yetunde Ogunbolude; Chenlu Dai; Edward T Bagu; Raghuveera Kumar Goel; Sayem Miah; Joshua MacAusland-Berg; Chi Ying Ng; Rajni Chibbar; Scott Napper; Leda Raptis; Frederick Vizeacoumar; Franco Vizeacoumar; Keith Bonham; Kiven Erique Lukong
Journal:  Oncotarget       Date:  2017-12-06

8.  Thymoquinone inhibits the metastasis of renal cell cancer cells by inducing autophagy via AMPK/mTOR signaling pathway.

Authors:  Yujiao Zhang; Yizeng Fan; Shangke Huang; Guanying Wang; Rui Han; Fuxi Lei; Anqi Luo; Xin Jing; Lin Zhao; Shanzhi Gu; Xinhan Zhao
Journal:  Cancer Sci       Date:  2018-10-28       Impact factor: 6.716

9.  Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.

Authors:  Fanjie Jin; Di Xiao; Tiansuo Zhao; Ming Yu
Journal:  Oncol Lett       Date:  2019-11-28       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.